[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fNHY9pXADa3g7N_MXzZUjqpqhwnfuEM77mU1kL7QuWHc":3},{"lesson":4},{"id":5,"slug":6,"article_id":7,"title":8,"body":9,"prevention":10,"framework_refs":11,"status":24,"created_at":25,"published_at":26,"article":27,"tags":31,"podcasts":50},"5d8ccec6-5535-44ba-88f0-abaffb9ad793","unencrypted-ble-transmission-and-dos-flaw-expose-apollo-pharmacy-glucose-monitor-users","285d1c4b-6b88-45d8-baac-76081c6b1836","Unencrypted BLE Transmission and DoS Flaw Expose Apollo Pharmacy Glucose Monitor Users","The Apollo Pharmacy APG-01 BT blood glucose monitor contains two serious vulnerabilities: one allowing passive interception of sensitive health data over Bluetooth Low Energy (CVE-2026-50034), and another enabling denial-of-service by monopolizing the device's single connection slot (CVE-2026-52866). These flaws are particularly dangerous because they target a medical device that handles protected health information (PHI), meaning real patients could have their glucose readings exposed or be locked out of a life-relevant monitoring tool. The situation is compounded by Apollo Pharmacy's failure to respond to CISA's coordination requests, leaving users with no vendor-issued remediation path. This highlights the broader risk of IoT and connected medical devices entering the market without adequate security validation or post-market vulnerability response processes.","**Immediate actions:**\n- Disable Bluetooth on the APG-01 BT device when not actively in use to minimize the attack surface for nearby adversaries.\n- Avoid using the device in public or high-density areas where malicious actors within BLE range could intercept transmissions.\n- Contact Apollo Pharmacy directly and request a security patch or firmware update timeline, escalating to regulatory bodies (e.g., FDA, CISA) if unresponsive.\n\n**Long-term improvements:**\n- Require BLE-enabled medical devices to implement authenticated and encrypted communication (e.g., BLE pairing with AES-128) before procurement or deployment.\n- Establish a vendor security assessment process that includes mandatory incident response SLAs as a condition of supplier contracts.\n- Maintain an inventory of all connected medical devices and track their CVE exposure using a vulnerability management platform.\n\n**Detection & monitoring measures:**\n- Deploy BLE monitoring tools in clinical environments to detect unauthorized scanning or connection attempts targeting medical devices.\n- Subscribe to CISA ICS-CERT advisories and automate alerting for CVEs affecting devices in your organization's medical device inventory.\n- Implement network\u002FRF anomaly detection to identify unusual Bluetooth activity patterns indicative of connection-slot exhaustion (DoS) attacks.",[12,13,14,15,16,17,18,19,20,21,22,23],"CIS Control 1: Inventory and Control of Enterprise Assets","CIS Control 3: Data Protection","CIS Control 7: Continuous Vulnerability Management","NIST SP 800-66 (HIPAA Security Rule Guidance)","NIST CSF PR.DS-2: Data-in-transit protection","NIST CSF RS.CO-2: Incident coordination with suppliers","NIST SP 800-30: Risk Assessment for IoT\u002FMedical Devices","FDA Postmarket Management of Cybersecurity in Medical Devices (2016 Guidance)","HIPAA Security Rule 45 CFR §164.312(e)(1): Transmission Security","GDPR Article 32: Security of processing (where applicable to EU users)","IEC 62443-4-2: Security for Industrial Automation and Control System Components","ITIL Service Transition: Supplier and contract management","published","2026-06-18T19:21:09.018953+00:00","2026-06-18T19:21:08.666+00:00",{"id":7,"url":28,"slug":29,"title":30},"https:\u002F\u002Fwww.cisa.gov\u002Fnews-events\u002Fics-medical-advisories\u002Ficsma-26-169-01","apollo-pharmacy-blood-glucose-monitoring-system-apg-01-bt-7d77cc","Apollo Pharmacy Blood Glucose Monitoring System APG-01 BT",[32,38,44],{"id":33,"name":34,"slug":35,"description":36,"color":37},"05757c8d-6b93-4194-b35d-7359e7d33b0e","Vulnerability Management","vulnerability-management","Missing scans, no risk prioritization","#fb923c",{"id":39,"name":40,"slug":41,"description":42,"color":43},"c0dcc566-3654-4d70-8ede-262a198e732f","Regulatory Compliance","regulatory-compliance","GDPR, NIS2, DORA, sector-specific violations","#ec4899",{"id":45,"name":46,"slug":47,"description":48,"color":49},"c8b843a5-d5a7-41d1-8d3b-cabded09d2ef","Data Protection","data-protection","Unencrypted data, missing DLP, poor classification","#3b82f6",[]]